FDA Drug recall D-0370-2021
Burro en Primavera, 2 capsules, UPC 638632431055
- FDA Drug
- Class II
- ongoing
- Published 2021-05-12
On 2021-05-12 the FDA classified a Class II recall of Burro en Primavera, 2 capsules, UPC 638632431055 by Qmart, citing marketed without Approved NDA/ANDA: FDA analysis results obtained the presence of tadalafil and/or sildenafil.
Read the official FDA Drug notice
| Agency | FDA Drug |
|---|---|
| Recall number | D-0370-2021 |
| Classification | Class II |
| Status | ongoing |
| Initiated | 2021-03-31 |
| Published | 2021-05-12 |
| Last updated | 2026-09-13 11:52 UTC |
| Company | Qmart |
| Distribution | US |
Product
Burro en Primavera, 2 capsules, UPC 638632431055
Reason
Marketed without Approved NDA/ANDA: FDA analysis results obtained the presence of tadalafil and/or sildenafil.
Identifiers
| upc | 638632431055 |
|---|---|
| code_info | All |
Status history
No status changes recorded since RecallRadar first saw this recall on 2026-09-13 11:52 UTC. Current status: ongoing.
Source
Official record: https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0370-2021%22
RecallRadar indexes public recall notices from the FDA, USDA FSIS, and CPSC. The official agency notice is the authoritative source. Always confirm details at the linked source before acting.